Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 4726 AL 4740

Significance of NF-κB as a pivotal therapeutic target in the neurodegenerative pathologies of Alzheimer's disease and multiple sclerosis

Srinivasan M, Lahiri DK.

Expert Opin Ther Targets. 2015 Apr;19(4):471-87. doi: 10.1517/14728222.2014.989834. Epub 2015 Feb 4.

Contractures in end-stage Alzheimer's disease may respond to low-dose corticosteroid treatment: report of three cases

Winegarden JA, Carr DB, Bradshaw Y.

J Palliat Med. 2015 Mar;18(3):208-9. doi: 10.1089/jpm.2014.0399. Epub 2015 Feb 6.

The metabolism hypothesis of Alzheimer's disease: from the concept of central insulin resistance and associated consequences to insulin therapy

Morgen K, Frölich L.

J Neural Transm (Vienna). 2015 Apr;122(4):499-504. doi: 10.1007/s00702-015-1377-5. Epub 2015 Feb 12.

Retinoic acid as a therapeutic option in Alzheimer's disease: a focus on cholinergic restoration

Szutowicz A, Bielarczyk H, Jankowska-Kulawy A, Ronowska A, Pawełczyk T.

Expert Rev Neurother. 2015 Mar;15(3):239-49. doi: 10.1586/14737175.2015.1008456. Epub 2015 Feb 15.

APOE-modulated Aβ-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective

Tai LM, Ghura S, Koster KP, Liakaite V, Maienschein-Cline M, Kanabar P, Collins N, Ben-Aissa M, Lei AZ, Bahroos N, Green SJ, Hendrickson B, Van Eldik LJ, LaDu MJ.

J Neurochem. 2015 May;133(4):465-88. doi: 10.1111/jnc.13072. Epub 2015 Mar 18.

Nanotherapeutic strategies for the treatment of Alzheimer's disease

Gu X, Chen H, Gao X.

Ther Deliv. 2015 Feb;6(2):177-95. doi: 10.4155/tde.14.97.

Design, synthesis and in vitro study of 5,6-diaryl-1,2,4-triazine-3-ylthioacetate derivatives as COX-2 and β-amyloid aggregation inhibitors

Dadashpour S, Tuylu Kucukkilinc T, Unsal Tan O, Ozadali K, Irannejad H, Emami S.

Arch Pharm (Weinheim). 2015 Mar;348(3):179-87. doi: 10.1002/ardp.201400400. Epub 2015 Feb 18.

Drosophila models of Alzheimer's disease: advances, limits, and perspectives

Bouleau S, Tricoire H.

J Alzheimers Dis. 2015;45(4):1015-38. doi: 10.3233/JAD-142802.

Building a roadmap for developing combination therapies for Alzheimer's disease

Perry D, Sperling R, Katz R, Berry D, Dilts D, Hanna D, Salloway S, Trojanowski JQ, Bountra C, Krams M, Luthman J, Potkin S, Gribkoff V, Temple R, Wang Y, Carrillo MC, Stephenson D, Snyder H, Liu E, Ware T, McKew J, Fields FO, Bain LJ, Bens C.

Expert Rev Neurother. 2015 Mar;15(3):327-33. doi: 10.1586/14737175.2015.996551.

Therapeutic approaches to modulating glutathione levels as a pharmacological strategy in Alzheimer's disease

Peter C, Braidy N, Zarka M, Welch J, Bridge W.

Curr Alzheimer Res. 2015;12(4):298-313. doi: 10.2174/1567205012666150302160308.

Vanutide cridificar and the QS-21 adjuvant in Japanese subjects with mild to moderate Alzheimer's disease: results from two phase 2 studies

Arai H, Suzuki H, Yoshiyama T.

Curr Alzheimer Res. 2015;12(3):242-54. doi: 10.2174/1567205012666150302154121.

Increased libido associated with donepezil treatment: a case report

Segrec N, Zaman R, Pregelj P.

Psychogeriatrics. 2016 Jan;16(1):70-2. doi: 10.1111/psyg.12113. Epub 2015 Mar 3.

Effect of the inhaled anesthetics isoflurane, sevoflurane and desflurane on the neuropathogenesis of Alzheimer's disease (review)

Jiang J, Jiang H.

Mol Med Rep. 2015 Jul;12(1):3-12. doi: 10.3892/mmr.2015.3424. Epub 2015 Mar 4.

Growth factor treatment to overcome Alzheimer's dysfunctional signaling

Lauzon MA, Daviau A, Marcos B, Faucheux N.

Cell Signal. 2015 Jun;27(6):1025-38. doi: 10.1016/j.cellsig.2015.02.018. Epub 2015 Mar 3.

Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review

West S, Bhugra P.

Br J Clin Pharmacol. 2015 Aug;80(2):221-34. doi: 10.1111/bcp.12621. Epub 2015 Jun 8.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias